Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Submitted by
admin
on September 9, 2022 - 10:57am
Source:
Motley Fool
News Tags:
Amgen
Soliris
biosimilars
ABP 959
Headline:
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
snippet:
The biotech giant shared encouraging results for its Soliris biosimilar.
The drug candidate could haul in $300 million in annual sales for Amgen.
The stock appears be a buy for dividend growth investors.
Do Not Allow Advertisers to Use My Personal information
